Kirilys Therapeutics
Kirilys is a biopharmaceutical company focused on developing precision oncology therapeutics that demonstrate high potency and selectivity against multiple cancers. Their oral drug formulation aims to enhance treatment efficacy for cancer patients and improve outcomes for those with chronic kidney disease.
- Biotechnology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Many cancer therapeutics lack the potency and selectivity needed to effectively target cancer cells, leading to off-target effects and limited efficacy. Patients with cancer and chronic kidney disease face additional challenges due to the potential for drug accumulation and toxicity.
Solution
Kirilys is developing precision oncology therapeutics designed to exhibit high potency and selectivity against multiple cancers. Their focus is on creating an oral drug formulation that enhances treatment efficacy for cancer patients, particularly those with chronic kidney disease. By targeting specific cancer pathways and minimizing off-target effects, Kirilys aims to improve patient outcomes and reduce the risk of adverse events.
Target Audience
The primary target audience includes cancer patients, particularly those with chronic kidney disease, and oncologists seeking more effective and targeted treatment options.
Features
- Oral drug formulation for ease of administration
- High potency against multiple cancer types
- Enhanced selectivity to minimize off-target effects
- Focus on improving outcomes for cancer patients with chronic kidney disease